Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy

Ornella Parolini, Giulio Alessandri, Laura De Girolamo, Enrico Lucarelli, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D'Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Augusto Pessina, Maria Luisa Torre

Risultato della ricerca: Contributo in rivistaArticolo in rivista

117 Citazioni (Scopus)

Abstract

Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.
Lingua originaleEnglish
pagine (da-a)2459-2473
Numero di pagine15
RivistaCURRENT PHARMACEUTICAL DESIGN
Volume19
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Cell- and Tissue-Based Therapy
  • Humans
  • Immunophenotyping
  • Mesenchymal Stromal Cells

Fingerprint

Entra nei temi di ricerca di 'Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy'. Insieme formano una fingerprint unica.

Cita questo